The Antitumor Assessment Core provides support for early discovery of effective antitumor agents and therapeutics. The Core provides resources, professional and technical expertise and advisory services related to the evaluation of agents with potential therapeutic activity, and works closely with investigators to establish in vivo mouse models, including Patient Derived Xenograft (PDX) models, for the design and execution of pharmacokinetic, toxicity and in vivo efficacy studies. The Core also determines the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. As such, the Core provides a major vehicle to facilitate pre-clinical studies, including GLP-compliant safety toxicology studies in support of IND applications, and is a major contributor to the translational mission of the Center. The Core helps investigators to design, plan, and execute their in vivo experiments, prepare animal protocols and grant applications involving animal studies, and analyze and summarize data for publication and for IND reporting. Importantly, the Core acts as a central coordinator for studies involving support from several Core facilities (including Animal Imaging, Comparative Medicine and Pathology, Tissue Procurement Service, Organic Synthesis, Integrated Genomics, Radiochemistry and Molecular Imaging Probes, and Molecular Cytology) so that studies are carried out properly and in a time- and cost-efficient manner.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Cruz, C; Castroviejo-Bermejo, M; Gutiérrez-Enríquez, S et al. (2018) RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol 29:1203-1210
Owosho, Adepitan A; Estilo, Cherry L; Huryn, Joseph M et al. (2018) A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head Neck Pathol 12:151-159
Burkhalter, Jack E; Atkinson, Thomas M; Berry-Lawhorn, J et al. (2018) Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions. Value Health 21:984-992
Aviki, Emeline M; Schleicher, Stephen M; Mullangi, Samyukta et al. (2018) Alternative payment and care-delivery models in oncology: A systematic review. Cancer 124:3293-3306
Chen, Feng; Ma, Kai; Madajewski, Brian et al. (2018) Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun 9:4141
Sadot, Eran; Zheng, Jian; Srouji, Rami et al. (2018) Hypophosphatemia as a Predictor of Organ-Specific Complications Following Gastrointestinal Surgery: Analysis of 8034 Patients. World J Surg :
Pietzak, Eugene J; Assel, Melissa; Becerra, Maria F et al. (2018) Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology 118:114-118
Hicks, Angel Mier; DeRosa, Antonio; Raj, Micheal et al. (2018) Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. Clin Colorectal Cancer 17:e207-e216
Phillips, Gregory S; Freites-Martinez, Azael; Hsu, Meier et al. (2018) Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. J Am Acad Dermatol 78:1102-1109
Chang, Matthew T; Penson, Alexander; Desai, Neil B et al. (2018) Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clin Cancer Res 24:1965-1973

Showing the most recent 10 out of 8799 publications